Screener
ANI Pharmaceuticals ANIP Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from ANI Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's debt-to-equity?
- ANI Pharmaceuticals (ANIP) reported debt-to-equity of 0.5× in Q2 2026.
- How has ANI Pharmaceuticals's debt-to-equity changed year-over-year?
- ANI Pharmaceuticals's debt-to-equity decreased by 29.9% year-over-year, from 0.7× to 0.5×.
- What is the long-term trend for ANI Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's debt-to-equity has grown at a -9.0% compound annual growth rate (CAGR), from 1× to 0.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about ANI Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude